Stereotaxis (STXS)
:STXS
STXS Stock Chart & Stats
$1.82
-$0.10(-4.18%)
At close: 4:00 PM EST
$1.82
-$0.10(-4.18%)
Day’s Range― - ―
52-Week Range$1.54 - $3.59
Previous CloseN/A
Volume282.58K
Average Volume (3M)583.61K
Market Cap
$179.91M
Enterprise Value$171.93M
Total Cash (Recent Filing)$13.42M
Total Debt (Recent Filing)$5.44M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding97,248,940
10 Day Avg. Volume380,338
30 Day Avg. Volume583,610
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue5.31
Enterprise Value/Gross Profit10.07
Enterprise Value/Ebitda-8.47
Forecast
1Y Price Target
$4.33Price Target Upside138.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.17
Revenue Forecast (FY)$41.10M
Bulls Say, Bears Say
Bulls Say
Manufacturing CapacityPlanned manufacturing ramps for GenesisX and MAGiC should enable higher system shipments and support growth in recurring consumable revenue.
Product CommercializationUS rollout of the MAGiC catheter and a broader launch of the GenesisX system expand commercial reach and are expected to boost system adoption.
Regulatory ApprovalsRegulatory approvals of MAGiC in the United States and GenesisX globally strengthen the product cycle and reduce regulatory uncertainty for future launches.
Bears Say
Market PressureBroader market pressures unrelated to operations have depressed the stock, creating valuation headwinds despite improving company fundamentals.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.54 and its highest was $3.59 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $179.91M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is May 12, 2026 which is in 40 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Mar 09, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.002.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 97,248,940 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went down -4.831%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (138.10% Upside)
$4.33 (138.10% Upside)
Hedge Fund Trend
Decreased
By 126.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.85%
12-Months-Change
Fundamentals
Return on Equity
-249.40%
Trailing 12-Months
Asset Growth
-10.50%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
STXS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated substantial strategic and regulatory progress — including U.S./EU approvals for GenesisX, MAGiC and MAGiC Sweep, double-digit revenue growth and clear commercial and manufacturing ramp plans — while also acknowledging meaningful operational challenges: catheter manufacturing constraints, a sharp quarter-on-quarter recurring revenue decline, increased negative free cash flow and persistently low system gross margins. Management provided concrete remediation plans (manufacturing scale-up, Osypka ramp to ~500 catheters/month, Synchrony commercialization, and mixed capital/placement sales models) and positive 2026 guidance (> $40M revenue), signaling a constructive outlook if execution continues. Overall, the highlights (regulatory wins, revenue growth, margin improvement potential and clear go-to-market plans) outweigh the operational lowlights, but execution risk remains material.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$4.33
▲(138.10% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
20.64% Insiders
6.15% Mutual Funds
29.02% Other Institutional Investors
38.65% Public Companies and
Individual Investors